Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001193125-26-267502 · ownership.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 02:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 2,658 | $5.82 | $15,478.33 |
DisclosureSEC source: 0001193125-26-057868 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 27,474 F3 · kind: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 4,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057868 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 9,722 Underlying: Common Stock · 4,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F6 · derivative.expiration_date: On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 4,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-057868 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 30,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 23:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 7,205 | $6.44 | $46,413.89 |
DisclosureSEC source: 0001193125-26-041516 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 25,271 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034072 · ownership.xml · derivative · entry 6 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 60,000 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary F6 · derivative.expiration_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 60,000 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034072 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 32,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 35,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034072 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 35,450 Underlying: Common Stock · 35,450 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. F5 · derivative.expiration_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,900 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001193125-26-034072 · ownership.xml · derivative · entry 4 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 70,900 Underlying: Common Stock · 70,900 shares Expires 2036-01-29 F4 · derivative.exercise_date: This option was granted on January 29, 2026 (the "2026 Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 191 | $6.59 | $1,258.69 |
DisclosureSEC source: 0001193125-26-031765 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 17,476 F2 · kind: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-031765 · ownership.xml · derivative · entry 6 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F6 · derivative.expiration_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 389 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-031765 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 0 Underlying: Common Stock · 389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F5 · derivative.expiration_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,884 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-031765 · ownership.xml · nonDerivative · entry 3 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · ownership.direct: Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| January 27, 2026 Filed Jan 30, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-031765 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 17,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 23:52 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,053 | $5.43 | $5,717.79 |
DisclosureSEC source: 0001193125-26-004953 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 17,278 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 23:52 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 2,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004953 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 2,994 Underlying: Common Stock · 2,994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F5 · derivative.expiration_date: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 23:52 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 2,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-004953 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 18,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 3,278 | $4.12 | $13,505.36 |
DisclosureSEC source: 0001193125-25-280126 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,412 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form. F2 · balance_after: Represents 91,370 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:25 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-109749 · ownership.xml · derivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. F1 · derivative.expiration_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:25 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0000950170-25-109749 · ownership.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-08-14 F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:25 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000950170-25-086234 · ownership.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2035-06-12 F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,711 | $3.96 | $6,775.56 |
DisclosureSEC source: 0000950170-25-022199 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 14,839 F3 · kind: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 4,861 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-022199 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 14,583 Underlying: Common Stock · 4,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F5 · derivative.expiration_date: On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 4,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-022199 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 16,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 31, 2025 Filed Feb 11, 2025 21:42 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017977 · ownership.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 23:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 144 | $3.11 | $447.78 |
DisclosureSEC source: 0000950170-25-010625 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 11,689 F2 · kind: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,883 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010625 · ownership.xml · derivative · entry 6 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,884 Underlying: Common Stock · 3,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F6 · derivative.expiration_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010625 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 389 Underlying: Common Stock · 388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F5 · derivative.expiration_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010625 · ownership.xml · nonDerivative · entry 3 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · ownership.direct: Represents 94,648 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-010625 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Wife Disclosed balance after: 11,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:29 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,056 | $4.31 | $4,551.36 |
DisclosureSEC source: 0000950170-25-003054 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 11,445 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:29 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 2,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-003054 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 5,988 Underlying: Common Stock · 2,994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F5 · derivative.expiration_date: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:29 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 2,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-003054 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 12,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 34,400 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0000950170-24-072992 · ownership.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 34,400 shares Expires 2034-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 02, 2024 Filed May 6, 2024 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,553 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-053774 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 0 Underlying: Common Stock · 1,553 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The restricted stock units were granted on May 2, 2022 and vested in two equal installments on May 2, 2023 and May 2, 2024. F5 · derivative.expiration_date: The restricted stock units were granted on May 2, 2022 and vested in two equal installments on May 2, 2023 and May 2, 2024. Read SEC document |
| May 02, 2024 Filed May 6, 2024 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 462 | $10.33 | $4,772.46 |
DisclosureSEC source: 0000950170-24-053774 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 9,507 F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units. This sale does not represent a discretionary trade by Ms. Ganot. Read SEC document |
| May 02, 2024 Filed May 6, 2024 22:48 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,553 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-053774 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 9,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 15:50 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 19,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016180 · ownership.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 19,444 Underlying: Common Stock · 19,444 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F2 · derivative.exercise_date: The RSUs were granted on the February 13, 2024 and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F2 · derivative.expiration_date: The RSUs were granted on the February 13, 2024 and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 22:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 139 | $7.99 | $1,110.61 |
DisclosureSEC source: 0000950170-24-008971 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 8,416 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sale does not represent a discretionary trade by Ms. Ganot. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,883 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-008971 · ownership.xml · derivative · entry 6 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,767 Underlying: Common Stock · 3,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On the grante date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F6 · derivative.expiration_date: On the grante date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-008971 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 777 Underlying: Common Stock · 388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F5 · derivative.expiration_date: On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-008971 · ownership.xml · nonDerivative · entry 3 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · ownership.direct: Represents 90,765 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-008971 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 8,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 2,993 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-002599 · ownership.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 8,982 Underlying: Common Stock · 2,993 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F5 · derivative.expiration_date: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,142 | $5.30 | $6,052.49 |
DisclosureSEC source: 0000950170-24-002599 · ownership.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 8,167 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 2,993 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-002599 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 9,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:33 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,583 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068068 · ownership.xml · derivative · entry 4 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common on a one-for-one basis. F5 · derivative.exercise_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. F5 · derivative.expiration_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:33 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-068068 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common on a one-for-one basis. F2 · ownership.direct: Represents 86,882 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 20:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,583 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-046760 · ownership.xml · derivative · entry 4 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,583 Underlying: Common Stock · 1,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. F5 · derivative.expiration_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 20:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-046760 · ownership.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · ownership.direct: Represents 85,299 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.